Section 35-103, Multiple-Seizure Electroconvulsive Therapy (MECT), is added to delineate the noncoverage policy for this treatment.

This section of the Coverage Issues Manual is the National Coverage Decision (NCD). NCDs are binding on all Medicare carriers, intermediaries, peer review organizations, Health Maintenance Organizations, Competitive Medical Plans, and Health Care Prepayment Plans. Under 42 CFR 422.256(b), an NCD that expands coverage is also binding on a Medicare+Choice Organization. In addition, an administrative law judge may not review an NCD. (See §1869 (f)(1)(A)(i) of the Social Security Act.)

These instructions should be implemented within your current operating budget.

DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted.
COVERAGE ISSUES

Nonselective (Random) Transfusions and Living-Related Donor Specific Transfusions (DST) in Kidney Transplantation 35-71
Electrotherapy for Treatment of Facial Nerve Paralysis (Bell’s Palsy) - Not Covered 35-72
Injection Sclerotherapy for Esophageal Variceal Bleeding 35-73
External Counterpulsation (ECP) for Severe Angina 35-74
Intraoperative Ventricular Mapping 35-75
Neuromuscular Electrical Stimulation (NMES) 35-77
Diagnostic Endocardial Electrical Stimulation (Pacing) 35-78
Anesthesia in Cardiac Pacemaker Surgery 35-79
Treatment of Kidney Stones 35-81
Pancreas Transplants 35-82
24-Hour Ambulatory Esophageal pH Monitoring 35-83
Injection Sclerotherapy for Esophageal Variceal Bleeding 35-73
Neuromuscular Electrical Stimulation (NMES) 35-77
Diagnostic Endocardial Electrical Stimulation (Pacing) 35-78
Anesthesia in Cardiac Pacemaker Surgery 35-79
Treatment of Kidney Stones 35-81
Pancreas Transplants 35-82
24-Hour Ambulatory Esophageal pH Monitoring 35-83
Stereotactic Cingulotomy as a Means of Psychosurgery - Not Covered 35-84
Implantation of Automatic Defibrillators 35-85
Gastric Balloon for Treatment of Obesity - Not Covered 35-86
Heart Transplants 35-87
Extracorporeal Photopheresis 35-88
Speech Pathology Services for the Treatment of Dysphagia 35-89
Extracorporeal Immunoadsorption (ECI) Using Protein A Columns for the Treatment of Patients With Idiopathic Thrombocytopenia Purpura (ITP) Failing Other Treatments 35-90
Laparoscopic Cholecystectomy 35-91
Transcendental Meditation - Not Covered 35-92
Lung Volume Reduction Surgery (Reduction Pneumoplasty, Also Called Lung Shaving or Lung Contouring) Unilateral or Bilateral By Open or Thoracoscopic Approach for Treatment of Emphysema and Chronic Obstructive Pulmonary Disease - Not Covered 35-93
Transmyocardial Revascularization With Laser - Not Covered 35-94
Partial Ventriculectomy (Also known as Ventricular Reduction, Ventricular Remodeling, or Heart Volume Reduction Surgery) - Not Covered 35-95
Cryosurgery of Prostate - Not Covered 35-96
Vertebral Axial Decompression (VAX-D) - Not Covered 35-97
Electrical Stimulation for the Treatment of Wounds 35-98
Abortion 35-99
Photodynamic Therapy 35-100
Treatment of Actinic Keratosis 35-101
Electrical Stimulation for the Treatment of Wounds 35-102
Multiple-Seizure Electroconvulsive Therapy 35-103

Supplies - Drugs

L-Dopa 45-1
Insulin Syringe 45-3
Vitamin B-12 Injections to Strengthen Tendons, Ligaments, Etc., of the Foot - Not Covered 45-4
Hydrophilic Contact Lens for Corneal Bandage 45-7
Lactriile and Related Substances - Not Covered 45-10
Autogenous Epidural Blood Graft 45-11
Porcine Skin and Gradient Pressure Dressing 45-12
Physician's Office Within an Institution - Coverage of Services and Supplies Incident to a Physician's Services 45-15
Certain Drugs Distributed by the National Cancer Institute 45-16
Transfer Factor for Treatment of Multiple Sclerosis Granulocyte Transfusions 45-18

Rev. 166
COVERAGE ISSUES

Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative Pain 45-19
Ethylenediamine-Teta-Acetic (EDTA) Chelation Therapy for Treatment of Atherosclerosis 45-20
Scalp Hypothermia During Chemotherapy to Prevent Hair Loss 45-21
Lymphocyte Immune Globulin, Anti-Thymocyte Globulin (Equine) 45-22
Dimethyl Sulfoxide (DMSO) 45-23
Anti-Inhibitor Coagulant Complex (AICC) 45-24
Supplies Used in the Delivery of Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES) 45-25
Platelet-Derived Wound Healing Formula 45-26
Blood Transfusions 45-27
Antigens Prepared for Sublingual Administration 45-28
Intravenous Iron Therapy 45-29
Photosensitive Drugs 45-30
Intravenous Immune Globulin for the Treatment of Autoimmune Mucocutaneous Blistering Diseases 45-31
Levocarnitine for Use in the Treatment of Carnitine Deficiency in ESRD Patients 45-32

Diagnostic Services

Cardiac Pacemaker Evaluation Services 50-1
Cytotoxic Food Tests - Not Covered 50-2
His Bundle Study 50-3
Gravlee Jet Washer 50-4
Thermography 50-5
Plethysmography 50-6
Ultrasound Diagnostic Procedures 50-7
Consultation Services Rendered by a Podiatrist in a Skilled Nursing Facility 50-8
Gastrophotography 50-9
Vabra Aspirator 50-10
Computerized Tomography 50-12
Magnetic Resonance Imaging 50-13
Magnetic Resonance Angiography 50-14
Electrocardiographic Services 50-15
Hemorheograph 50-16
Laboratory Tests - CRD Patients 50-17
Electron Microscope 50-18
Pronouncement of Death 50-19
Diagnostic Pap Smears 50-20
Screening Pap Smears and Pelvic Examinations for Early Detection of Cervical Cancer or Vaginal Cancer 50-20.1
Mammograms 50-21
Challenge Ingestion Food Testing 50-22
Histocompatibility Testing 50-23
Hair Analysis 50-24
Esophageal Manometry 50-25
Dental Examination Prior to Kidney Transplantation 50-26
Xenon Scan 50-27
Hospital and Skilled Nursing Facility Admission Diagnostic Procedures 50-28
Cytogenetic Studies 50-29
Nuclear Radiology Procedure 50-30
Evoked Response Tests 50-31
Percutaneous Transluminal Angioplasty (PTA) 50-32
Uroflowmetric Evaluations 50-33
Obsolete or Unreliable Diagnostic Tests 50-34
Sweat Test 50-35
Positron Emission Transverse Tomography (PET) Scans 50-36
Noninvasive Tests of Carotid Function 50-37

Rev. 166
The use of electrical stimulation for the treatment of wounds is considered an adjunctive therapy. Electrical stimulation will be covered only after appropriate standard wound therapy has been tried for at least 30-days and there are no measurable signs of healing. This 30-day period can begin while the wound is acute. Measurable signs of improved healing include a decrease in wound size, either surface area or volume, decrease in amount of exudates and decrease in amount of necrotic tissue. Standard wound care includes: optimization of nutritional status; debridement by any means to remove devitalized tissue; maintenance of a clean, moist bed of granulation tissue with appropriate moist dressings; and necessary treatment to resolve any infection that may be present. Standard wound care based on the specific type of wound includes: frequent repositioning of a patient with pressure ulcers (usually every 2 hours); off-loading of pressure and good glucose control for diabetic ulcers; establishment of adequate circulation for arterial ulcers; and the use of a compression system for patients with venous ulcers.

Continued treatment with electrical stimulation is not covered if measurable signs of healing have not been demonstrated within any 30-day period of treatment. Electrical stimulation must be discontinued when the wound demonstrates 100 per-cent epithelialized wound bed.

Any form of electromagnetic therapy for the treatment of chronic wounds will not be covered.

This service can only be covered when performed by a physician, physical therapist, or incident to a physician service. Evaluation of the wound is an integral part of wound therapy. When a physician, physical therapist, or a clinician incident to a physician, performs electrical stimulation, that practitioner must evaluate the wound and contact the treating physician if the wound worsens. If electrical stimulation is being used, wounds must be evaluated at least monthly by the treating physician.

Unsupervised use of electrical stimulation for wound therapy will not be covered, as this use has not been found to be medically reasonable and necessary.

35-103 Multiple Electroconvulsive Therapy (MECT) (Effective for services provided on or after April 1, 2003.)

The clinical effectiveness of the multiple-seizure electroconvulsive therapy has not been verified by scientifically controlled studies. In addition, studies have demonstrated an increased risk of adverse effects with multiple seizures. Accordingly, MECT cannot be considered reasonable and necessary and is not covered by the Medicare program.